SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment
Dear BOPA member,
Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer, who are at risk of serious adverse events (AE) related to their first-line systemic anti-cancer treatment (SACT). This is important because 38% of these patients treated with SACT will encounter an acute hospital visit due to an AE in their last year of life. The proposed risk score leverages real-world data to estimate the likelihood of hospitalisations caused by AEs. By providing a clearer understanding of treatment risks, this tool aims to improve communication between clinicians and patients about potential AE, ultimately supporting better SACT decision-making through individualised assessments of serious AE risks for patients with incurable lung cancer.
However, it is not yet understood how prescribers would use this risk model in practice. The work aims to understand how this risk score can impact a clinician’s treatment recommendations. In order to achieve this, an online survey has been designed that aims to understand clinician’s perceptions of a decision support tools for Lung Cancer treatment.
Please find the link to this survey here: https://qualtrics.ucl.ac.uk/jfe/form/SV_7339WZAz0rwQk6O
